Do you have a rare kidney disease like FSGS, IgA Nephropathy, or other Nephrotic Syndrome condition? You’ve come to the right place. Access breakthrough clinical trials, expert care, and one-on-one patient support here.
This study will examine the effectiveness of Acthar® Gel in adults subjects with FSGS who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio, which is a marker of kidney damage).
Definitely consider the trials. It's so exciting that pharma is finally putting money into FSGS, and we have to participate to help find a cure! I've already participated in one and it was easy and painless.
Welcome to the Kidney Health Gateway. Please answer some basic questions about you, or your loved one's, rare chronic kidney disease. We will use this information to provide you with a list of clinical trials and research opportunities in your area.
Please provide us with your contact information so that we can keep you updated as new research opportunities become available. We will never share or sell your information.
After entering your information, you will be asked 4 questions about your or your loved one's kidney disease.